SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Adobe, Inc. is a global technology company, which engages in the provision of digital marketing and media solutions. It operates through the following segments: Digital Media, Digital Experience, and Publishing and Advertising. The Digital Media segment offers products and services that enable individuals, teams, businesses, and enterprises to create, publish, and promote content anywhere and accelerate productivity by transforming view, share, engage with and collaborate on documents and creative content. The Digital Experience segment focuses on integrated platform and set of products, services, and solutions that enable businesses to create, manage, execute, measure, monetize, and optimize customer experiences that span from analytics to commerce. The Publishing and Advertising segment includes legacy products and services that address diverse market opportunities, including eLearning solutions, technical document publishing, web conferencing, document and forms platform, web app development, high-end printing, and Adobe Advertising offerings. The company was founded by Charles M. Geschke and John E. Warnock in December 1982 and is headquartered in San Jose, CA.

Adobe Inc

Adobe is facing significant market volatility as investors weigh strong record revenue against the shock of an announced CEO transition. While some in the community see the leadership change as a long-term positive and an attractive buying opportunity given recent valuation lows, others are fueling downward pressure due to lingering concerns over AI-driven competition and the shifting landscape of creative software.

SentinelOne, Inc. engages in the provision of endpoint security software that detects, models, and predicts threat behavior to block attacks on any computing device. Its services include vigilance, support, and training. The company was founded by Tomer Weingarten and Almog Cohen in 2013 and is headquartered in Mountain View, CA.

SentinelOne Inc - Ordinary Shares - Class A

SentinelOne Inc

SentinelOne is facing significant investor skepticism as the stock languishes near all-time lows, with community discourse heavily divided between those betting on long-term growth and acquisition potential versus frustrated bears concerned about share dilution and intense competition. While sentiment is fueled by robust ARR growth and cybersecurity demand, investors are actively debating the impact of AI-driven tools on the company's competitive moat and future guidance.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is seeing significant investor attention driven by a combination of restored Nasdaq compliance and ongoing discussions surrounding its major equity stakes in companies like Babcock & Wilcox. While some in the community highlight the stock's extremely low P/E ratio and potential for a short squeeze, others remain cautious, debating the impact of upcoming 10-K filings and the broader market's reaction to the company's debt management strategies.

Rubrik, Inc. engages in the provision of cloud data management solutions. Its solutions include backup and recovery, VM backup, Microsoft 365, ransom ware recovery, database backup, cloud solutions, and Polaris sonar. Rubrik products include data protection, data threat analytics, data security posture and cyber recovery. The company was founded by Bipul Sinha, Arvind Jain, Soham Mazumdar, and Arvind Nithrakashyap in December 2013 and is headquartered in Palo Alto, CA.

Rubrik Inc. - Ordinary Shares - Class A

Rubrik Inc. - Class A

Rubrik is facing significant downward pressure and community frustration as the stock struggles to maintain gains despite delivering strong earnings and growth metrics. Investors are currently debating whether the sell-off is a result of broader software sector rotation and valuation compression or if insider selling and AI-related narrative shifts are permanently weighing on the share price.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is rallying as investors react to the departure of a high-level FDA official previously perceived as a significant barrier to regulatory approvals in the rare disease space. The community is increasingly bullish, citing positive pivotal data and strong anticipation for the company's upcoming late-breaking presentation at a major medical conference as key drivers for potential rapid regulatory progress.

Ulta Beauty, Inc. engages in the retail of beauty products. The company has one reportable segment, which includes retail stores, salon services, and e-commerce. Its products include makeup, skin care, tools and brushes, fragrance, and bath and body. The company was founded on January 9, 1990 and is headquartered in Bolingbrook, IL.

Ulta Beauty Inc

Ulta Beauty is experiencing heightened volatility following a recent quarterly earnings report where mixed guidance fueled intense debate among retail traders. The community is actively discussing the company's long-term competitive position against rivals like Sephora and the broader impact of consumer spending shifts on specialty retail.

Eastman Kodak Co. engages in the provision of analog and digital innovations. It operates through the following segments: Traditional Printing, Digital Printing, Advanced Materials and Chemicals, and Brand. The Traditional Printing segment consists of Prepress Solutions, which includes Kodak's digital offset plate offerings and computer-to-plate imaging solutions. The Digital Printing segment contains Electrophotographic Printing Solutions, Prosper, Versamark and Software. The Advanced Materials and Chemicals segment consists of four lines of business: Industrial Film and Chemicals, Motion Picture, Advanced Materials and Functional Printing, and Kodak Services for Business (KSB). The Brand segment includes licensing of the Kodak brand to third parties. The company was founded by George Eastman in 1880 and is headquartered in Rochester, NY.

Eastman Kodak Co.

Eastman Kodak is seeing increased investor activity as the community anticipates potential government contracts related to national security and domestic pharmaceutical manufacturing, particularly following recent management updates and sector-wide interest in reshoring supply chains. Enthusiastic shareholders are actively discussing the company's strong cash position and its strategic pivot into specialized materials, viewing the current stock consolidation as a potential accumulation phase ahead of upcoming earnings and future policy catalysts.

Elicio Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cancer immunotherapies. It focuses on its Amphiphile platform for trafficking lymph nodes. The company was founded by Darrell Irvine in August 2011 and is headquartered in Boston, MA.

Elicio Therapeutics Inc.

Elicio Therapeutics Inc

Elicio Therapeutics is trending as the community closely monitors the company's progress in its Phase 2 AMPLIFY-7P trial for the ELI-002 cancer vaccine, with investors expressing strong bullish sentiment regarding early efficacy signals. The discourse is heavily focused on the company's potential to address KRAS-mutant solid tumors, with many discussing the trial's ability to demonstrate disease-free survival benefits and the strategic implications of the company's ongoing capital management.

PagerDuty, Inc. engages in the provision of a digital operations management platform. Its products include incident management, automation, status pages, integrations, artificial intelligence for information technology operations (AIOps), customer service operations, and stakeholders’ communications. The firm's solutions include incident management transformation, operations center modernization, automation standardization, customer experience operations, digital operations resiliency, scaled service ownership, and remote-location operations. It also serves the financial services, healthcare, non-profit, public sector, and retail industries. The company was founded by Andrew Miklas, Baskar Puvanathasan, and Dan Alexandru Solomon in 2009 and is headquartered in San Francisco, CA.

Pagerduty Inc

PagerDuty is currently trending as investors debate the stock's valuation and potential for M&A, with many in the community highlighting the disconnect between the company's profitability and its suppressed share price. While some are frustrated by recent performance and technical trends, others remain optimistic about its long-term viability, consistently pointing to its balance sheet, cash position, and the possibility of a buyout as key catalysts.

ServiceTitan, Inc. engages in the collection of field service activities required to install, maintain, and service the infrastructure and systems of residences and commercial buildings. The company was founded by Ara Mahdessian and Vahe Kuzoyan on June 8, 2008 and is headquartered in Glendale, CA.

ServiceTitan Inc. - Ordinary Shares - Class A

ServiceTitan 

ServiceTitan is trending as investors react to the company's latest quarterly earnings, which highlighted strong revenue growth and improved margins that beat analyst expectations. While the community is actively debating the company's valuation and long-term potential as an essential "operating system" for the trades industry, some participants are also discussing the impact of recent analyst rating updates and the broader sentiment surrounding software sector volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Danish pharmaceutical company Novo Nordisk (NVO) on Tuesday said that it has submitted an application to the European Medicines Agency (EMA) for the approval of a new and higher dose of its blockbuster obesity treatment, Wegovy.NYSE-listed shares of the company were trading over 1% higher at the time of writing.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916360">submission</a> to the EMA is based on data from two trials investigating the efficacy and safety of a higher dose of Semaglutide, the active ingredient in Wegovy, in people with obesity with or without type 2 diabetes. While one of the trials included 1,407 adults with obesity and not diabetes, the other included 512 adults with obesity and type 2 diabetes.The new 7.2 mg dose of Wegovy demonstrated a substantial average weight loss of 21% in people with obesity, with a third of participants losing 25% or more of their body weight compared with placebo, the company said.Data also indicated that Semaglutide 7.2 mg had a well-tolerated safety profile consistent with Semaglutide 2.4 mg, <a href="https://stocktwits.com/symbol/NVO">Novo Nordisk</a> added.Ludovic Helfgott, executive vice president and head of Product &amp; Portfolio Strategy at Novo Nordisk, said that the new dose was developed as a tailored option for people in need of additional support to achieve meaningful, sustained weight loss.In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union.Wegovy is among Novo Nordisk’s blockbuster drugs. In the first quarter, Wegovy sales stood at DKK 17,360 million ($2.72 billion), marking a growth of 85% from the corresponding period of 2024, and accounting for over 22% of the company’s total sales in the period.On Stocktwits, retail sentiment around Novo Nordisk stayed unmoved within the ‘bearish’ territory over the past 24 hours while message volume stayed at ‘extremely low’ levels.<figure class="image"><img style="aspect-ratio:1364/128;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_08_at_11_24_34_AM_png_6c076523e1.webp" alt="NVO's Sentiment Meter and Message Volume as of 11:25 a.m. ET on July 8, 2025 | Source: Stocktwits" width="1364" height="128"><figcaption>NVO's Sentiment Meter and Message Volume as of 11:25 a.m. ET on July 8, 2025 | Source: Stocktwits</figcaption></figure>NVO stock is down by over 18% this year and by about 51% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/lvmh-stock-surges-as-luxury-goods-maker-appoints-longtime-arnault-confidante-to-lead-americas-turnaround/chFvvSpR5WK">LVMH Stock Surges As Luxury Goods Maker Appoints Longtime Arnault Confidante To Lead Americas Turnaround: Retail Remains Bearish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Seeks Approval For Higher Wegovy Dose In Europe

In addition to the submission to the EMA, Novo Nordisk aims to make the higher dose of Wegovy widely available throughout the European Union.

Current Price	$33.51
Prev Close	$34.20
Open	$33.51
Dividend Yield	N/A
50-Day Moving Average	$34.80
Beta	N/A
Avg. Volume	1,534.53
PE Ratio	N/A

52-Week High	$36.38
52-Week Low	$24.62
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

GGRW
Gabelli ETFs Trust - Gabelli Growth Innovators ETF

Feed

News

Sentiment

Fundamentals

Info

Latest GGRW News

GGRWGabelli ETFs Trust - Gabelli Growth Innovators ETF